List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/26762/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Use of Germline <i>BRCA</i> Testing in Patients With Ovarian Cancer and Commercial Insurance. JAMA Network Open, 2022, 5, e2142703.	5.9	13
2	Reply to W. E. Rosa et al and T. N. Townsend et al. Journal of Clinical Oncology, 2022, 40, 312-314.	1.6	0
3	The Oncology Care Model and Adherence to Oral Cancer Drugs: A Difference-in-Differences Analysis. Journal of the National Cancer Institute, 2022, 114, 871-877.	6.3	4
4	Association of the Oncology Care Model With Value-Based Changes in Use of Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 114, 39-46.	0.8	3
5	Impact of the Oncology Care Model on Use of Supportive Care Medications During Cancer Treatment. Journal of Clinical Oncology, 2022, , JCO2102342.	1.6	6
6	Variation of use of targeted therapies and molecular diagnostic testing by practice type for non-small cell lung cancer and colorectal cancer Journal of Clinical Oncology, 2022, 40, 6551-6551.	1.6	0
7	The impact of physician-hospital integration on spending and quality of oncology care Journal of Clinical Oncology, 2022, 40, 1584-1584.	1.6	Ο
8	How Do Claimsâ€Based Measures of Endâ€ofâ€Life Care Compare to Family Ratings of Care Quality?. Journal of the American Geriatrics Society, 2021, 69, 900-907.	2.6	4
9	Evaluation of Reliability and Correlations of Quality Measures in Cancer Care. JAMA Network Open, 2021, 4, e212474.	5.9	12
10	Measuring disparities in quality of oncology care across oncology practices Journal of Clinical Oncology, 2021, 39, 6533-6533.	1.6	1
11	Assessment of Patient Attribution to Care From Medical Oncologists, Surgeons, or Radiation Oncologists After Newly Diagnosed Cancer. JAMA Network Open, 2021, 4, e218055.	5.9	5
12	Impact of the Oncology Care Model on use of bone supportive medications, antiemetics, and growth factors Journal of Clinical Oncology, 2021, 39, 1517-1517.	1.6	0
13	Using Consistently Low Performance to Identify Low-Quality Physician Groups. JAMA Network Open, 2021, 4, e2117954.	5.9	Ο
14	US Trends in Opioid Access Among Patients With Poor Prognosis Cancer Near the End-of-Life. Journal of Clinical Oncology, 2021, 39, 2948-2958.	1.6	53
15	Association of Participation in the Oncology Care Model With Medicare Payments, Utilization, Care Delivery, and Quality Outcomes. JAMA - Journal of the American Medical Association, 2021, 326, 1829.	7.4	34
16	Coding-Driven Changes In Measured Risk In Accountable Care Organizations. Health Affairs, 2021, 40, 1909-1917.	5.2	4
17	Disparities in outpatient visits for mental health and/or substance use disorders during the COVID surge and partial reopening in Massachusetts. General Hospital Psychiatry, 2020, 67, 100-106.	2.4	67
18	Physician and facility drivers of spending variation in locoregional prostate cancer. Cancer, 2020, 126, 1622-1631.	4.1	1

#	Article	IF	CITATIONS
19	U.S. trends and racial/ethnic disparities in opioid access among patients with poor prognosis cancer at the end of life (EOL) Journal of Clinical Oncology, 2020, 38, 7005-7005.	1.6	8
20	Reliability and correlations among quality measures for lung, breast, and colorectal cancer Journal of Clinical Oncology, 2020, 38, 2073-2073.	1.6	0
21	The Comparative Advantage of Medicare Advantage. American Journal of Health Economics, 2019, 5, 281-301.	3.0	5
22	Association Between Clinical Practice Group Adherence to Quality Measures and Adverse Outcomes Among Adult Patients With Diabetes. JAMA Network Open, 2019, 2, e199139.	5.9	10
23	Social Risk Adjustment of Quality Measures for Diabetes and Cardiovascular Disease in a Commercially Insured US Population. JAMA Network Open, 2019, 2, e190838.	5.9	17
24	Classifying Stage IV Lung Cancer From Health Care Claims: A Comparison of Multiple Analytic Approaches. JCO Clinical Cancer Informatics, 2019, 3, 1-19.	2.1	8
25	Early Findings From the Oncology Care Model Evaluation. Journal of Oncology Practice, 2019, 15, e888-e896.	2.5	16
26	What drives variation in spending for breast cancer patients within geographic regions?. Health Services Research, 2019, 54, 97-105.	2.0	5
27	The Comparative Advantage of Medicare Advantage. American Journal of Health Economics, 2019, 5, 281-301.	3.0	1
28	Targeted Supplemental Data Collection — Addressing the Quality-Measurement Conundrum. New England Journal of Medicine, 2018, 378, 979-981.	27.0	12
29	Inference With Difference-in-Differences With a Small Number of Groups. Medical Care, 2018, 56, 97-105.	2.4	33
30	Comparison of Approaches for Aggregating Quality Measures in Populationâ€based Payment Models. Health Services Research, 2018, 53, 4477-4490.	2.0	4
31	Factors Contributing To Geographic Variation In End-Of-Life Expenditures For Cancer Patients. Health Affairs, 2018, 37, 1136-1143.	5.2	32
32	Classifying lung cancer stage from health care claims with a clinical algorithm or a machine-learning approach Journal of Clinical Oncology, 2018, 36, 6589-6589.	1.6	1
33	Understanding factors contributing to geographic variations in end-of-life expenditures Journal of Clinical Oncology, 2018, 36, 10008-10008.	1.6	1
34	Screening Mammography for Free: Impact of Eliminating Cost Sharing on Cancer Screening Rates. Health Services Research, 2017, 52, 191-206.	2.0	22
35	Geographic Variation in Quality of Care for Commercially Insured Patients. Health Services Research, 2017, 52, 849-862.	2.0	15
36	Early Impact Of CareFirst's Patient-Centered Medical Home With Strong Financial Incentives. Health Affairs, 2017, 36, 468-475.	5.2	17

#	Article	IF	CITATIONS
37	Quality of Primary Care for Children With Disabilities Enrolled in Medicaid. Academic Pediatrics, 2017, 17, 443-449.	2.0	12
38	An administrative stage inference algorithm for use in patients receiving chemotherapy for colorectal cancer Journal of Clinical Oncology, 2017, 35, e18121-e18121.	1.6	1
39	Classifying Lung Cancer Severity with Ensemble Machine Learning in Health Care Claims Data. Proceedings of Machine Learning Research, 2017, 68, 25-38.	0.3	16
40	Variations in Oncologist Recommendations for Chemotherapy for Stage IV Lung Cancer: What Is the Role of Performance Status?. Journal of Oncology Practice, 2016, 12, 653-662.	2.5	9
41	Dartmouth Atlas Areaâ€Level Estimates of Endâ€ofâ€Life Expenditures: How Well Do They Reflect Expenditures for Prospectively Identified Advanced Lung Cancer Patients?. Health Services Research, 2016, 51, 1584-1594.	2.0	8
42	Pay for Performance in Medicaid: Evidence from Three Natural Experiments. Health Services Research, 2016, 51, 1444-1466.	2.0	13
43	The Impact of a Tiered Network on Hospital Choice. Health Services Research, 2015, 50, 1628-1648.	2.0	19
44	Tumor Board Participation Among Physicians Caring for Patients With Lung or Colorectal Cancer. Journal of Oncology Practice, 2015, 11, e267-e278.	2.5	54
45	Association of Actual and Preferred Decision Roles With Patient-Reported Quality of Care. JAMA Oncology, 2015, 1, 50.	7.1	170
46	Development of the Children With Disabilities Algorithm. Pediatrics, 2015, 136, e871-e878.	2.1	22
47	Family perspectives on aggressive cancer care near the end of life Journal of Clinical Oncology, 2015, 33, 6517-6517.	1.6	0
48	Decisions about cancer treatment: Matching of actual to preferred roles and patient ratings of care Journal of Clinical Oncology, 2014, 32, 6533-6533.	1.6	0
49	Developing and evaluating composite measures of cancer care quality Journal of Clinical Oncology, 2014, 32, 187-187.	1.6	0
50	Effectiveness of cisplatin versus carboplatin-based doublet chemotherapy in elderly Medicare patients with advanced non-small cell lung cancer Journal of Clinical Oncology, 2014, 32, 284-284.	1.6	0
51	Tumor boards among physicians caring for lung and colorectal cancer patients Journal of Clinical Oncology, 2014, 32, 179-179.	1.6	0
52	The role of families in decisions about cancer treatments Journal of Clinical Oncology, 2013, 31, 6528-6528.	1.6	3
53	Survival of Older Patients With Cancer in the Veterans Health Administration Versus Fee-for-Service Medicare. Journal of Clinical Oncology, 2012, 30, 1072-1079.	1.6	68
54	Reasons for underuse of recommended therapies for colorectal and lung cancer in the Veterans Health Administration. Cancer, 2012, 118, 3345-3355.	4.1	71

#	Article	IF	CITATIONS
55	Regional Variation in Medication Adherence. Forum for Health Economics and Policy, 2011, 14, .	0.8	5
56	Is Spending More Always Wasteful? The Appropriateness Of Care And Outcomes Among Colorectal Cancer Patients. Health Affairs, 2008, 27, 159-168.	5.2	53
57	Care following Acute Myocardial Infarction in the Veterans Administration Medical Centers: A Comparison with Medicare. Health Services Research, 2004, 39, 1773-1792.	2.0	33
58	The Role of Information in Medical Markets: An Analysis of Publicly Reported Outcomes in Cardiac Surgery. American Economic Review, 2004, 94, 342-346.	8.5	146
59	Selection of Related Multivariate Means. Journal of the American Statistical Association, 2003, 98, 7-16.	3.1	26
60	A multiple imputation strategy for incomplete longitudinal data. Statistics in Medicine, 2001, 20, 2741-2760.	1.6	22
61	Title is missing!. Health Services and Outcomes Research Methodology, 2001, 2, 221-245.	1.8	43
62	Applying Bayesian ideas to the development of medical guidelines. , 1999, 18, 117-137.		30